In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) estimated that 137 million U.S. adults, more than half of all adults, are eligible for semagludtide for weight loss, diabetes management, or prevention of recurrent cardiovascular events.
Newly updated stroke prevention guidelines from the American Heart Association and American Stroke Association say women with endometriosis and women with early-onset menopause are at greater risk.
As year-end insurance deductibles are met and plans are made for a healthy start to the new year, many people choose to have elective health procedures such as bariatric surgery around this time. If considering this type of weight loss surgery, what should you keep in mind? A Hackensack Meridian Health expert shares some tips.
Ten years after undergoing bariatric surgery as teens, over half of study participants demonstrated not only sustained weight loss, but also resolution of obesity-related conditions, such as type 2 diabetes, high blood pressure and high cholesterol, according to the report published in the New England Journal of Medicine.
Increasing ketones in the blood through a keto diet or supplements may help put irregular menstrual cycles back on schedule or even restart a period that appears to have stalled for good, new research suggests.
Setting out to prove that movement indeed is medicine for older adults with chronic knee and hip pain, Wake Forest University researchers have received a $5.7 grant from the National Institutes of Health (NIH) to conduct a five-year study.
Technology applications in the fitness industry continue to build momentum as Wearable Technology, Mobile Exercise Apps and Data-Driven Training Technology all appear in the top 10 of the 2025 ACSM Worldwide Fitness Trends. The report was published today by the American College of Sports Medicine in its November/December issue of ACSM’s Health & Fitness Journal®.
Newer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according to a study presented at the American College of Surgeons (ACS) Clinical Congress 2024 in San Francisco, California. Further, a second study presented at the meeting found that this increasingly popular class of weight loss drugs, called glucagon-like peptide-1 receptor agonists, or GLP-1 RA, appears safe and may be a novel approach to treating obesity when used before bariatric surgery.
The Patient-Centered Outcomes Research Institute (PCORI) today announced $37 million in funding awards through its Health Systems Implementation Initiative (HSII). These awards will support 25 projects implementing PCORI-funded comparative clinical effectiveness research (CER) findings in participating HSII health systems.
Case Western Reserve University School of Medicine identifies a potential new approach to address the opioid overdose epidemic—which has devastated families and communities nationally. Semaglutide was found to lower opioid overdoses in people with opioid-use disorder (OUD) and type 2 diabetes (T2D).
Mount Sinai Health System, a leading health system in the United States and one of the largest in the New York City area, and Noom, the leading digital health care company committed to chronic disease prevention and empowering people to live better and healthier lives, have partnered to provide patients with a whole-person approach to healthy, long-lasting weight loss.
Scientists from Immanuel Kant Baltic Federal University analyzed scientific works dedicated to the role of proteins prohibitins in the development of obesity. It turned out that these proteins promote development of inflammation both in separate cells and the whole organism. This happens because prohibitins stimulate emission of anti-inflammatory substances by immune cells, and also participate in destruction of mitochondria damaged during oxidative stress. Obtained information points to the fact that prohibitins can become targets for medicine aimed at struggle with obesity consequences. Results of the research are published in the magazine Frontiers in Molecular Biosciences.
Wegovy (semaglutide) now has Medicare approval for coverage among people with obesity and cardiovascular disease but no diabetes; a study looks at what level of risk might make someone eligible.
To promote high-quality, person-directed care across the spectrum of kidney health and diseases the American Society of Nephrology (ASN) is releasing its inaugural Kidney Health Guidance (KHG) on the Management of Obesity in Persons Living with Kidney Diseases in the Journal of the American Society of Nephrology (JASN) on September 18, 2024.
Participating in a high volume of exercise over a short period of time, such as cycling hundreds of miles in a few days, could reduce body fat levels without weight loss. The first-of-its-kind study is published ahead of print in the American Journal of Physiology-Endocrinology and Metabolism and has been chosen as an APSselect article for September.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
